Twice-Yearly Lenacapavir Demonstrates Sustained Impact on He

– Patient-Reported Outcomes From the CAPELLA Trial Align With the Demonstrated Safety and Tolerability Profile of Lenacapavir –– Analyses Show Oral Bridging Maintains Virologic Suppression When Subcutaneous Lenacapavir Doses are Missed –FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today...

Related Keywords

Paris , France General , France , Brisbane , Queensland , Australia , United States , Foster City , California , Switzerland , United Arab Emirates , Israel , Canada , United Kingdom , Informationfor Sunlenca , Jean Michel Molina , Jared Baeten , Exchange Commission , Gilead Sciences , Clinical Development , Nasdaq , European Union , Gilead Public Affairs , Gilead Sciences Inc , Gilead On Twitter Sciences , Head Of The Infectious Diseases Department , Patient Reported Outcomes From , Align With , Demonstrated Safety , Tolerability Profile , Vice President , Numeric Pain Rating Scale , Visual Analogue Scale , Pain Rating Scale , Paris Cit , Infectious Diseases , Infectious Diseases Department , Important Safety Information , Safety Information , Antiretroviral Pregnancy Registry , Funders Concerned About , Private Securities Litigation Reform Act , Quarterly Report , Prescribing Informationfor Sunlenca ,